Publications by authors named "S Moutereau"
Voxelotor modifies hemoglobin-oxygen affinity improving anemia and reducing hemolysis in sickle cell patients. However, the impact of Voxelotor on fetal hemoglobin (HbF) levels is unknown. We describe here variations of percentage of HbF measured by high performance liquid chromatography and mean corpuscular fetal Hb in a cohort of sickle cell patients treated with Voxelotor at Henri Mondor Sickle Cell Referral Center.
View Article and Find Full Text PDFArticle Synopsis
- Transfusion is crucial for treating sickle cell disease (SCD) and requires matching blood groups to avoid complications like alloimmunization and hemolytic reactions, with African ancestry donors generally providing the best match.
- A study analyzed transfusion protocols and the frequency of G6PD deficiency in blood units from these donors, revealing that 35.1% of SCD patients had no antibodies and that G6PD deficiency was found in 9 units from Afro-Caribbean donors.
- While the transfusion protocols followed guidelines to prevent immunological issues, the high rate of G6PD deficiency in compatible units poses concerns regarding the quality and outcomes of transfusions, necessitating further evaluation.
Voxelotor (GBT440, OXBRYTA®) appeared recently as one of the possible treatments for sickle cell disease. This molecule, by binding the alpha globin of hemoglobin, causes hyperaffinity of the latter for oxygen and reduces its polymerization properties. Several therapeutic trials have been able to show its effectiveness on certain aspects of sickle cell disease; thus, the french HAS (High Authority of Health) college issued an early access authorization and, since 2021, this treatment can be offered to patients under a temporary authorization for use.
View Article and Find Full Text PDFAims: Iron deficiency (ID) is common in patient with chronic heart failure (HF) and has been widely studied. In contrast, data concerning ID in cardiac amyloidosis (CA) are limited. Amyloidosis is a severe and fatal systemic disease, characterized by an accumulation of amyloid fibrils in various tissues/organs, including nerves, kidneys, gastrointestinal tract, and heart.
View Article and Find Full Text PDF